Nothing Special   »   [go: up one dir, main page]

BR112014027413A2 - biomarcadores para terapia com inibidor de iap - Google Patents

biomarcadores para terapia com inibidor de iap

Info

Publication number
BR112014027413A2
BR112014027413A2 BR112014027413A BR112014027413A BR112014027413A2 BR 112014027413 A2 BR112014027413 A2 BR 112014027413A2 BR 112014027413 A BR112014027413 A BR 112014027413A BR 112014027413 A BR112014027413 A BR 112014027413A BR 112014027413 A2 BR112014027413 A2 BR 112014027413A2
Authority
BR
Brazil
Prior art keywords
subject
iap inhibitor
biomarkers
inhibitor therapy
biological sample
Prior art date
Application number
BR112014027413A
Other languages
English (en)
Inventor
Emery Caroline
Porter Dale
Robinson Douglas
Scott Cameron John
Venkatesan Kavitha
Wang Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014027413A2 publication Critical patent/BR112014027413A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: “biomarcadores para terapia com inibidor de iap”. a presente invenção refere-se a um método de seleção de um indivíduo que possui câncer para tratamento com um inibidor de iap, incluindo um método de análise de uma amostra biológica de um indivíduo com câncer incluindo a determinação de um nível de expressão de mrna de tnf e ripk1 e um ou mais dos biomarcadores cxlc10, ccl5, nfkbia, herc5, cdyl, stk39 e mapk14 na amostra biológica tirada do indivíduo, em que o nível de expressão dos biomarcadores em comparação a um controle fornece um indicador do fato do indivíduo ter uma maior probabilidade de responder a um inibidor de iap tal como (s)-n-((s)-1-ciclohexil-2-{(s)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metilamino-propionamida.
BR112014027413A 2012-05-04 2013-05-03 biomarcadores para terapia com inibidor de iap BR112014027413A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642899P 2012-05-04 2012-05-04
PCT/US2013/039362 WO2013166344A1 (en) 2012-05-04 2013-05-03 Biomarkers for iap inhibitor therapy

Publications (1)

Publication Number Publication Date
BR112014027413A2 true BR112014027413A2 (pt) 2017-06-27

Family

ID=48407833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027413A BR112014027413A2 (pt) 2012-05-04 2013-05-03 biomarcadores para terapia com inibidor de iap

Country Status (20)

Country Link
US (1) US9353419B2 (pt)
EP (1) EP2844764B1 (pt)
JP (1) JP6513019B2 (pt)
KR (1) KR20150011822A (pt)
CN (1) CN104284988A (pt)
AU (1) AU2013256182A1 (pt)
BR (1) BR112014027413A2 (pt)
CA (1) CA2871995A1 (pt)
CL (1) CL2014002976A1 (pt)
ES (1) ES2593046T3 (pt)
HK (1) HK1202589A1 (pt)
IL (1) IL235315A0 (pt)
MA (1) MA37475A1 (pt)
MX (1) MX2014013429A (pt)
PH (1) PH12014502461A1 (pt)
RU (1) RU2014148779A (pt)
SG (1) SG11201406837TA (pt)
TN (1) TN2014000443A1 (pt)
TW (1) TW201347760A (pt)
WO (1) WO2013166344A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
CA3080943A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Novel agents targeting inhibitor of apoptosis proteins
JP7257397B2 (ja) 2017-11-13 2023-04-13 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US7718600B2 (en) 2000-09-29 2010-05-18 The Trustees Of Princeton University IAP binding compounds
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
MXPA06008095A (es) 2004-01-16 2007-03-28 Univ Michigan Mimeticos de smac conformacionalmente restringidos y sus usos.
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
EP1740173A4 (en) 2004-03-23 2009-05-27 Genentech Inc AZABICYCLOOCTAN IAP INHIBITORS
ES2396195T3 (es) 2004-04-07 2013-02-19 Novartis Ag Inhibidores de IAP
DK1778718T3 (da) 2004-07-02 2014-11-10 Genentech Inc Iap-inhibitorer
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
KR20070043831A (ko) 2004-07-12 2007-04-25 아이디유엔 파마슈티칼즈, 인코포레이티드 테트라펩티드 유사체
US7456209B2 (en) 2004-07-15 2008-11-25 Tetralogic Pharmaceuticals Corporation IAP binding compounds
WO2006069063A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
EP1960551A2 (en) * 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CN101529254A (zh) * 2006-10-19 2009-09-09 诺瓦提斯公司 有机化合物
BRPI0717411A2 (pt) * 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
KR20100024923A (ko) 2007-04-30 2010-03-08 제넨테크, 인크. Ｉａｐ의 억제제
US20120015352A1 (en) * 2009-01-29 2012-01-19 Otto-Von-Guericke-Universitat Magdeburg Method of determining sensitivity of human or non-human animal cells to an iap antagonist
ES2805347T3 (es) * 2009-02-11 2021-02-11 Caris Mpi Inc Perfilado molecular de tumores
CN102612651A (zh) * 2009-09-18 2012-07-25 诺瓦提斯公司 Iap抑制剂化合物的生物标志物
CN101956014B (zh) 2010-09-30 2014-05-28 中山大学 一种用于鼻咽癌早期诊断的外周血7个基因标志物的检测试剂盒

Also Published As

Publication number Publication date
CA2871995A1 (en) 2013-11-07
TW201347760A (zh) 2013-12-01
EP2844764A1 (en) 2015-03-11
RU2014148779A (ru) 2016-06-27
WO2013166344A1 (en) 2013-11-07
MA37475A1 (fr) 2016-05-31
JP2015523056A (ja) 2015-08-13
CN104284988A (zh) 2015-01-14
HK1202589A1 (zh) 2015-10-02
ES2593046T3 (es) 2016-12-05
KR20150011822A (ko) 2015-02-02
US9353419B2 (en) 2016-05-31
IL235315A0 (en) 2014-12-31
MX2014013429A (es) 2014-12-08
EP2844764B1 (en) 2016-06-22
TN2014000443A1 (en) 2016-03-30
SG11201406837TA (en) 2014-11-27
US20150105434A1 (en) 2015-04-16
AU2013256182A1 (en) 2014-11-13
PH12014502461A1 (en) 2014-12-22
JP6513019B2 (ja) 2019-05-15
CL2014002976A1 (es) 2015-02-13

Similar Documents

Publication Publication Date Title
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112014010955A2 (pt) sistema e método para processar amostras
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
AR084831A1 (es) Terapia anticancer mediante inhibidores de quinasa
IN2014DN04226A (pt)
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
BR112014032892A2 (pt) processo de amplificação por rcp e de detecção de pelo menos uma sequência-alvo nucleotídica, dispositivo de amplificação e de detecção rápida de pelo menos uma sequência-alvo nucleotídica e estojo de amplificação por rcp e de detecção de pelo menos uma sequência nucleotídica-alvo
MX2018014922A (es) Metodos para detectar norovirus.
BR112014024487A2 (pt) métodos para aumentar a eficácia da terapia baseada em cd37
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
BR112012018545A2 (pt) método de determinação e confirmação da presença de um hpv em uma amostra
BR112014027413A2 (pt) biomarcadores para terapia com inibidor de iap
BR112015004653A2 (pt) método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas
BR112015027249A2 (pt) método de diagnóstico de câncer
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]